U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBANDRONIC ACID

SMILES

CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

HIDE SMILES / InChI

Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers. In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Ibandrix in Ecuador and Bondrova in Bangladesh.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Boniva

Approved Use

Unknown
Primary
Boniva

Approved Use

Unknown
Primary
Boniva

Approved Use

Directions: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
90.64 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
549.24 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
32.38 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / month multiple, oral
Dose: 100 mg, 1 times / month
Route: oral
Route: multiple
Dose: 100 mg, 1 times / month
Sources:
unhealthy, 55–74 years
n = 183
Health Status: unhealthy
Condition: osteoporosis
Age Group: 55–74 years
Sex: M+F
Population Size: 183
Sources:
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources: Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources: Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (1%)
Sources: Page: p. 24
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources: Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources: Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (2%)
Sources: Page: p. 24
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources: Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources: Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (2%)
Sources: Page: p. 24
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Other AEs: Agranulocytosis, Acute pancreatitis...
Other AEs:
Agranulocytosis (serious, 1 patient)
Acute pancreatitis (serious, 1 patient)
Acute pyelonephritis (serious, 1 patient)
Sepsis (serious, 1 patient)
Concussion (serious, 1 patient)
Poisoning (serious, 1 patient)
Follicle centre lymphoma diffuse small cell lymphoma (serious, 1 patient)
Malignant tongue neoplasm (serious, 1 patient)
Transient ischaemic attack (serious, 1 patient)
Pulmonary embolism (serious, 1 patient)
Deep vein thrombosis (serious, 2 patients)
Influenza (below serious, 4 patients)
Arthralgia (below serious, 8 patients)
Rheumatoid arthritis (below serious, 4 patients)
Sources:
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Other AEs: Death, Syncope...
Other AEs:
Death (serious, 1 patient)
Syncope (serious, 2 patients)
Pneumonia (serious, 1 patient)
Retinal detachment (serious, 1 patient)
Rectal haemorrhage (serious, 1 patient)
Pneumoconiosis (serious, 1 patient)
Nasopharyngitis (below serious, 7 patients)
Nausea (below serious, 4 patients)
Upper respiratory tract infection (below serious, 3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Musculoskeletal disorder NOS 1%
Disc. AE
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources: Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources: Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources: Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources: Page: p. 24
Musculoskeletal disorder NOS 2%
Disc. AE
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources: Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources: Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources: Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources: Page: p. 24
Musculoskeletal disorder NOS 2%
Disc. AE
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources: Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources: Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources: Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources: Page: p. 24
Influenza below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Rheumatoid arthritis below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Arthralgia below serious, 8 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Acute pancreatitis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Acute pyelonephritis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Agranulocytosis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Concussion serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Follicle centre lymphoma diffuse small cell lymphoma serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Malignant tongue neoplasm serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Poisoning serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Pulmonary embolism serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Sepsis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Transient ischaemic attack serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Deep vein thrombosis serious, 2 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
Upper respiratory tract infection below serious, 3 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Nausea below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Nasopharyngitis below serious, 7 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Death serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Pneumoconiosis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Pneumonia serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Rectal haemorrhage serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Retinal detachment serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Syncope serious, 2 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Dosing regimens and main adverse events of bisphosphonates.
2001 Aug
Effect of ibandronate on bone loss and renal function after kidney transplantation.
2001 Jul
Ibandronate in the treatment of prostate cancer associated painful osseous metastases.
2002
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
2002 Apr 22
Treatment of hypercalcemia of malignancy with bisphosphonates.
2002 Dec
Bisphosphonates for prevention of postmenopausal osteoporosis.
2002 Feb
Bisphosphonates for cancer patients: why, how, and when?
2002 Jul
Novel therapeutic options for osteoporosis.
2002 Jul
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.
2002 Jul
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
2002 May 6
Drugs in development: bisphosphonates and metalloproteinase inhibitors.
2003
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
2003 Apr
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.
2003 Aug
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
2003 Aug
Is ibandronate effective in multiple myeloma?
2003 Dec
[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
2003 Dec
Injectable drug dampens bone loss.
2003 Dec
[How to treat tumor-induced hypercalcemia].
2003 Dec 15
Antitumor effects of bisphosphonates.
2003 Feb 1
Mechanisms of osteolytic bone metastases in breast carcinoma.
2003 Feb 1
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.
2003 Jan
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.
2003 Jul
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
2003 Jun
Review of ibandronate in the treatment of osteoporosis.
2003 Mar
Effects of ibandronate on inflammation in mouse antigen-induced arthritis.
2003 May
Ibandronate: new options in the treatment of osteoporosis.
2003 Nov
Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples.
2003 Nov 3
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
2003 Oct
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
2004 Apr
[Ibandronate].
2004 Feb
Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats.
2004 Feb
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
2004 Jan
Hypercalcemia of malignancy.
2004 Jan
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
2004 Mar
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
2004 Mar
Nephrotoxicity of third-generation, intravenous bisphosphonates.
2004 Mar 1
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
2004 Mar 22
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
2004 May
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.
2004 May
Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats.
2004 May
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
2004 Oct
Patents

Sample Use Guides

Oral: 150 mg orally once a month on the same day each month IV Injection: 3 mg by IV injection over 15 to 30 seconds every three months.
Route of Administration: Other
Cells were cultivated in cell culture flasks at 37_Cand5%CO2. The culture media were as recommended by the American Type Culture Collection (ATCC) for MDA-MB-231 breast cancer DMEM (Sigma-Aldrich, St. Louis, MO, USA), which contained 10% fetal calf serum (FCS); PC-3 prostate carcinoma DMEM-F12 (Sigma-Aldrich) with 10% FCS. MG-63 and U2-OS osteosarcoma were cultured in AlphaMEM (Biochrom, Berlin, Germany) medium containing 10% FBS. For the HMC1.1 cell line, we used Iscove’s Modified Dulbecco’s Medium (IMDM; Thermo Fisher Scientific, Waltham, MA) supplemented with 260 nM thioglycerol (Sigma-Aldrich) and20%fetal bovine serum (FBS). All culture media contained 10 mg/mL gentamycin (Sigma-Aldrich). To guarantee optimal growth, cells were split two times a week and reseeded at a density of 2-5 x 105 cells/mL. One day after splitting, 32 mMsimvastatin (Sigma-Aldrich) or 150 mM ibandronate (Sigma-Aldrich) were added to the culture medium for 72 hours. This is the dose that attenuated cell proliferation with a half maximal effect. NADP/NADPH analyses were performed directly in 96-well culture plates after 24 or 48 hours
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:57:11 GMT 2023
Edited
by admin
on Sat Dec 16 15:57:11 GMT 2023
Record UNII
UMD7G2653W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBANDRONIC ACID
EMA EPAR   INN   MART.   MI   WHO-DD  
INN  
Official Name English
IBANDRONATE [VANDF]
Common Name English
IBANDRONIC ACID ACCORD
Brand Name English
NSC-722623
Code English
Ibandronic acid [WHO-DD]
Common Name English
IBANDRONIC ACID [EMA EPAR]
Common Name English
IBANDRONIC ACID [MART.]
Common Name English
IASIBON
Brand Name English
IBANDRONATE
VANDF  
Common Name English
BONDENZA
Brand Name English
(1-HYDROXY-3-(METHYLPENTYLAMINO)PROPYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
IBANDRONIC ACID [MI]
Common Name English
IBANDRONIC ACID SANDOZ
Brand Name English
ibandronic acid [INN]
Common Name English
IBANDRONIC ACID TEVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NCI_THESAURUS C67439
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONDENZA (WITHDRAWN: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NCI_THESAURUS C443
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS HALAVEN (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: WOUNDS AND INJURIES)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NDF-RT N0000007707
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
WHO-VATC QM05BA06
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONVIVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: NEOPLASTIC PROCESSES)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS DESTARA (WITHDRAWN: CANCER, HYPERCALCIMA)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
WHO-ATC M05BA06
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
LIVERTOX 494
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS XGEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NDF-RT N0000175579
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL997
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID5048340
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
MERCK INDEX
m6182
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY Merck Index
FDA UNII
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
RXCUI
115264
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
ALTERNATIVE
IUPHAR
3059
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
NCI_THESAURUS
C65874
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
MESH
C073007
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DRUG CENTRAL
1404
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
WIKIPEDIA
IBANDRONIC ACID
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
NSC
722623
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
SMS_ID
100000085439
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
EVMPD
SUB08092MIG
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
RXCUI
115265
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DRUG BANK
DB00710
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
PUBCHEM
60852
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
INN
7189
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DAILYMED
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
CAS
114084-78-5
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
LACTMED
Ibandronate
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose). Unabsorbed ibandronate is eliminated unchanged in the feces.
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE

ORAL ADMINISTRATION